Ifinatamab Deruxtecan: A Next-Generation Drug Targeting B7-H3 in Small Cell Lung Cancer
In this article
It is difficult to appreciate the drug's value without understanding the context. Small cell lung cancer accounts for approximately 15% of all lung cancers; it is strongly associated with smoking, highly aggressive and rapidly progresses to the metastatic (extensive) stage. In extensive-stage SCLC (ES-SCLC), first-line treatment (platinum-based chemotherapy + immunotherapy) initially works in most patients, but the disease almost always returns, and in the second line options are both few and of limited efficacy. Ifinatamab deruxtecan targets precisely this gap — the group of "patients progressing after platinum".
What is B7-H3 (CD276), and why is it a good target?
B7-H3 is an immune checkpoint protein in the B7 family. Its most important feature is this: while it is almost absent from most normal/healthy tissues, it is frequently expressed at moderate-to-high levels in small cell lung cancer cells; moreover, it is associated with larger tumours and shorter survival. This "abundant in tumours, scarce in healthy tissue" profile makes it an ideal "address label" for an ADC — enabling the drug to find the tumour while relatively sparing healthy tissue.
Ifinatamab deruxtecan is an antibody-drug conjugate (ADC) — a "smart bomb" composed of three parts: (1) a target-finding antibody, (2) a powerful chemotherapy payload , and (3) a connection between the two that breaks at the right location: a linker . The concept is simple but powerful: deliver chemotherapy directly into the tumour cell rather than distributing it throughout the body.
🎯 THREE PARTS, ONE TARGET
Antibody: A humanised anti-B7-H3 IgG1 monoclonal antibody. Its job is to circulate through the bloodstream, find tumour cells bearing B7-H3 and lock onto them.
Linker: A tetrapeptide-based, cleavable linker. After the antibody binds to the tumour cell and is taken inside, the linker breaks within the cell and releases its payload.
Payload: DXd — a topoisomerase I inhibitor (an exatecan derivative). This potent chemotherapy molecule kills the tumour cell by preventing it from copying its DNA. Through the "bystander effect", it can also pass into surrounding target-negative cells.
Ifinatamab deruxtecan was discovered by Daiichi Sankyo, and joint development began in October 2023 under a global co-development/commercialisation agreement with Merck. The clinical programme is based on a family of trials called "IDeate".
The current excitement around ifinatamab deruxtecan is based on the results of the phase 2 IDeate-Lung01 trial. The study enrolled previously treated patients with extensive-stage SCLC (most had received multiple lines, and 81% had received immunotherapy), without selecting patients by B7-H3 expression — it was therefore tested in an "all-comer" population.
IDEATE-LUNG01 — PRIMARY ANALYSIS (overall population, n=137 evaluable)
- Confirmed objective response rate (ORR): 48,2% (3 complete responses + 63 partial responses).
- Duration of response (DoR): median 5,3 months.
- Progression-free survival (PFS): median 4,9 months.
- Overall survival (OS): median 10,3 months.
- 12 mg/kg cohort (selected dose): even stronger — ORR ~54,8%, PFS ~5,5 months, OS ~11,8 months.
- Activity against brain metastases: intracranial confirmed response rate ~37,8% — crucial, since brain metastases are common in SCLC.
No potent drug is free of side effects; what matters is the balance between efficacy and toxicity. The safety profile of ifinatamab deruxtecan is generally considered "manageable", but a class effect requires attention.
IDEATE-LUNG01 — SAFETY SUMMARY
- Treatment-related adverse event (any grade): %89,8.
- Grade ≥3 adverse event: %36,5.
- Grade 5 (fatal) adverse event: %4,4.
- Most common side effects: fatigue, gastrointestinal (nausea, etc.) and haematological (reduced blood counts) events.
- Interstitial lung disease (ILD)/pneumonitis: adjudicated ILD in 17 patients (%12,4); 6 of these were grade ≥3. This is a known class effect of deruxtecan-based ADCs and requires close monitoring.
Why does interstitial lung disease (ILD) matter?
ILD/pneumonitis (inflammatory injury to lung tissue) is a known, serious and sometimes fatal side effect of all ADCs using the deruxtecan platform (including trastuzumab deruxtecan). Therefore, early recognition of respiratory symptoms (cough, shortness of breath, fever), regular imaging and, when necessary, stopping treatment and starting steroids are critically important in patients receiving ifinatamab deruxtecan. Although the drug has strong efficacy, this toxicity requires proactive monitoring — particularly in the SCLC population, which already has lung disease.
| Status / Region | Current status | Details |
|---|---|---|
| FDA — Breakthrough Therapy | GRANTED (Aug 2025) | For ES-SCLC progressing after platinum. Based on IDeate-Lung01 + PanTumor01. The collaboration's first BTD. |
| FDA — Priority Review | ACCEPTED (2026) | Decision date (PDUFA): 10 October 2026. Indication: previously treated ES-SCLC. |
| Phase 3 confirmation (IDeate-Lung02) | ONGOING | Against chemotherapy in relapsed SCLC; expected to provide the basis for full approval. |
| Europe (EMA) / Türkiye (TİTCK) | NOT APPROVED | Not yet licensed; access through clinical research or exceptional routes (below). |
What do "Breakthrough Therapy" and "Priority Review" mean?
Both are FDA tools for accelerating the process. Breakthrough Therapy (BTD)is granted for early evidence showing a substantial advantage over existing treatments for a serious disease, and accelerates development. Priority Review shortens the review period after submission (approximately ~6 months rather than the standard ~10 months). Neither is an "approval" — but both are positive signals. Actual approval will become clear with the FDA's decision on 10 October 2026.
Ifinatamab deruxtecan is not yet licensed in Türkiye and cannot be routinely prescribed. At present, access may be possible through limited, exceptional routes.
POSSIBLE ACCESS ROUTES
- Participation in clinical research: Global trials such as IDeate-Lung02 (phase 3) operate across multiple regions. If an open and suitable ifinatamab deruxtecan trial is available in Türkiye, a patient meeting the criteria may be evaluated through their own oncologist. This is the most concrete route; the current situation should be checked by the physician.
- Foreign medicines / individual import (TİTCK): A mechanism operating for drugs licensed in another country. Since ifinatamab deruxtecan is not yet fully licensed in any country (the FDA decision is in October 2026), this route is not currently practical.
- Compassionate early access (compassionate use): For patients who cannot benefit from licensed treatments and have no suitable trial; dependent on the manufacturer's support for the programme.
Even if FDA approval arrives (expected in October 2026), European and Turkish licensing and SGK reimbursement are separate, subsequent processes. Expectations of routine access in the near future should therefore remain realistic.
⚡ WHY DOES IT MATTER?
Small cell lung cancer is an aggressive cancer that has seen no substantial progress for decades and has few second-line options. As the first strong B7-H3-targeted ADC candidate, ifinatamab deruxtecan has the potential to fill this gap. A ~48-55% response rate in heavily pretreated patients and ~38% activity against brain metastases are exceptional for this field. The FDA's granting of both Breakthrough Therapy and Priority Review also indicates high regulatory expectations.
✅ STRENGTHS
Built on the proven deruxtecan/DXd ADC platform. High response in IDeate-Lung01 without B7-H3 selection (all-comers). Activity against brain metastases — a common and difficult-to-treat problem in SCLC. A clear phase 3 confirmation programme (IDeate-Lung02) and an attempt to move into earlier treatment lines (the IDeate-Lung03 combination) are available. Strong corporate backing (Daiichi Sankyo + Merck).
⚠️ LIMITATIONS AND CAUTIONS
The main evidence currently comes from a single-arm phase 2 study — randomised phase 3 data against chemotherapy (IDeate-Lung02) are essential to establish a definitive advantage. Interstitial lung disease (ILD/pneumonitis) is a serious class effect; grade 5 adverse events (4,4%) should not be underestimated. Response rates are high, but durations (DoR ~5,3 months) are modest — durability is an important question. The drug is not yet fully approved in any country; there is no routine access in Türkiye.
🩺 IMPLICATIONS FOR PRACTICE
If approved, ifinatamab deruxtecan could become an important second-/later-line option in previously treated extensive-stage SCLC — particularly for patients with brain metastases. If introduced into use, ILD monitoring (respiratory symptoms, imaging) should be an integral part of the treatment protocol. For now, this is an agent with "high promise, awaiting phase 3 and approval"; it has not yet replaced existing standards (topotecan, lurbinectedin).
❓ QUESTIONS FOR THE FUTURE
Will phase 3 IDeate-Lung02 confirm a survival advantage over chemotherapy? Will the FDA approve it on 10 October 2026, and for which indication? Can the combination (IDeate-Lung03) move into the first line? Will targeting B7-H3 also work in tumours beyond SCLC (prostate, other solid tumours)? Can ILD risk be better predicted and managed? When will access become available in Europe/Türkiye?
🗣 How should this be explained to patients and their families?
"Ifinatamab deruxtecan is a next-generation 'smart drug' (antibody-drug conjugate) being developed for small cell lung cancer. By finding a target called B7-H3 on the surface of cancer cells, it delivers powerful chemotherapy directly to the tumour. It has shown promising results in previously treated patients and has been active even against disease that has spread to the brain. However, it is still undergoing research and approval; it is not yet licensed in our country and is not routinely available. Serious side effects, such as lung inflammation, need close monitoring. Be sure to discuss its suitability for you and current clinical research options with your own oncologist."
Ifinatamab deruxtecan is generating real excitement in small cell lung cancer, a field long short of hope — and this excitement has a sound scientific basis: a proven ADC platform (deruxtecan), a well-chosen target (B7-H3), high response rates and noteworthy activity against brain metastases. The FDA's successive Breakthrough Therapy and Priority Review designations reflect these expectations at the regulatory level as well; the decision on 10 October 2026 could be a turning point for the field. However, an honest assessment requires waiting for phase 3 confirmation (IDeate-Lung02), for response duration and overall survival data to mature, and close monitoring of serious toxicities such as interstitial lung disease. For Türkiye, the picture is clear: a strongly promising prospect, but not an accessible treatment today. This report aims to present the drug's promise and limitations together — because sound hope in oncology begins with complete, balanced information.
References
- Ahn MJ, Rudin CM, Johnson ML, et al. Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial. Journal of Clinical Oncology 2025, DOI 10.1200/JCO-25-02142 (WCLC 2025, LBA OA06.03).
- Rudin CM, Ahn MJ, Johnson M, et al. Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer: interim analysis of IDeate-Lung01 (OA04.03). J Thorac Oncol 2024;19:S15-S16 (WCLC 2024; 12 mg/kg ORR 52,4% vs 8 mg/kg 26,1%).
- Owonikoko TK, Byers LA, Cheng Y, et al. IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab deruxtecan vs treatment of physician's choice in relapsed SCLC. J Clin Oncol 2024 (suppl; TPS8126); design publication PMC12536792 (~540 patients, NCT06203210).
- Merck & Daiichi Sankyo. Ifinatamab deruxtecan granted Priority Review in the U.S. for previously treated ES-SCLC; PDUFA date 10 October 2026. Press release, 2026.
- FDA / Merck / Daiichi Sankyo. Breakthrough Therapy Designation for I-DXd in pretreated ES-SCLC. August 2025.
- IASLC. Ifinatamab Deruxtecan Demonstrates High Response Rate in Previously Treated ES-SCLC: Phase 2 IDeate-Lung01 (TRAE 89,8%; grade ≥3 36,5%; grade 5 4,4%; ILD in 17 patients, 6 grade ≥3). WCLC 2025.
- Clinical review. Clinical progress of B7-H3 targeted antibody drug conjugate ifinatamab deruxtecan for small-cell lung cancer. PubMed 40418751 (12 mg/kg: ORR 54,8%, PFS 5,5 months, OS 11,8 months; intracranial response 37,8%).
- ClinicalTrials.gov. NCT05280470 (IDeate-Lung01), NCT06203210 (IDeate-Lung02), NCT04145622 (IDeate-PanTumor01).
- TİTCK. Guideline on the Use of Foreign Medicines and the Compassionate Early Access Programme.
This article is medical news/a review for informational purposes; it does not provide individual treatment recommendations. At the time this article was prepared, ifinatamab deruxtecan was not fully licensed in any country; in the US, it had received FDA Breakthrough Therapy and Priority Review designations, with a decision date (PDUFA) of 10 October 2026. These designations do not mean "approval". The drug is not licensed in other countries, including Europe and Türkiye; statements such as "under FDA review" or "presented at a congress" do not mean that the drug is accessible or can be prescribed in Türkiye. The main efficacy evidence to date comes from phase 2 (IDeate-Lung01) and is largely single-arm; definitive efficacy and superiority to chemotherapy await confirmation by the ongoing phase 3 trial (IDeate-Lung02). Interstitial lung disease (ILD)/pneumonitis is a known, serious and sometimes fatal class effect of deruxtecan-based ADCs and requires close monitoring. Patients should always discuss treatment decisions and access options with their own oncologists in light of their individual disease characteristics and current approval status. All data were verified against Journal of Clinical Oncology, WCLC presentations, the IDeate-Lung02 design publication, official Merck/Daiichi Sankyo announcements and FDA notifications.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.